Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Phenotype modification

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    13 result(s) found for: Phenotype modification. Displaying page 1 of 1.
    EudraCT Number: 2017-000810-44 Sponsor Protocol Number: FSJD-PMM2-2016 Start Date*: 2017-05-31
    Sponsor Name:Fundació Sant Joan de Déu
    Full Title: Phase II clinical trial to evaluate the effectiveness and safety of acetazolamide in the treatment of cerebellar syndrome in patients with PMM2-CDG deficiency.
    Medical condition: Cerebellar syndrome
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029205 - Nervous system disorders 10008072 Cerebellar syndrome PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-004869-18 Sponsor Protocol Number: 030547 Start Date*: 2008-07-03
    Sponsor Name:UHB NHS Foundation Trust
    Full Title: Evaluation of the relative severity of pulmonary neutrophilic inflammation and therapeutic modification with IV Prolastin by means of 18 FDG PET/CT scanning in subjects with alpha1-antitrypsin defi...
    Medical condition: The medical condition is emphysema and will be investigated in subjects with alpha 1-antitrypsin deficiency.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001811 Alpha-1 proteinase inhibitor deficiency LLT
    9.1 10014563 Emphysema pulmonary LLT
    9.1 10010952 COPD LLT
    9.1 10006458 Bronchitis chronic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-005013-37 Sponsor Protocol Number: IDEA v1 Start Date*: 2006-04-06
    Sponsor Name:University of Leeds
    Full Title: A multi-centre randomised double dummy double blind study comparing two regimens of combination induction therapy in early DMARD naive Rheumatoid Arthritis: The IDEA study (Infliximab as Induction ...
    Medical condition: Early Rheumatoid Arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-019742-12 Sponsor Protocol Number: GIMEMALAL1610 Start Date*: 2012-06-06
    Sponsor Name:G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO
    Full Title: A Phase II study with a sequential clofarabine-cyclophosphamide combination schedule as salvage therapy for refractory and relapsed acute lymphoblastic leukemia (ALL) in adult patients
    Medical condition: Acute Lymphoblastic Leukemia (ALL)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000844 Acute lymphoblastic leukaemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-005798-36 Sponsor Protocol Number: HOVON100ALL/EORTC06083 Start Date*: 2009-08-31
    Sponsor Name:HOVON Foundation
    Full Title: Clofarabine added to prephase and consolidation therapy in acute lymphoblastic leukemia in adults.
    Medical condition: Primary previously untreated B or T-lineage ALL (excluding ALL with mature B-cell phenotype, but including Philadelphia positive or BCR-ABL positive ALL) or previously untreated T-LBL
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    17.0 100000004864 10043028 T-lymphoblastic lymphoma (Kiel Classification) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-007177-20 Sponsor Protocol Number: Sirolimus_Liver_Tolerance Start Date*: 2009-09-07
    Sponsor Name:Hospital Clinic Barcelona
    Full Title: EFECTO DEL SIROLIMUS SOBRE LOS BIOMARCADORES RELACIONADOS CON LA TOLERANCIA EN RECEPTORES DE TRASPLANTE HEPÁTICO ESTABLES
    Medical condition: Stable liver transplant recipients identified as non-tolerant (i.e. requiring indefinite immunosuppressive therapy) on the basis of peripheral blood transcriptional biomarkers.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10024716 Liver transplantation LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-000935-15 Sponsor Protocol Number: PRODIGE70-CIRCULATE Start Date*: 2019-09-10
    Sponsor Name:Centre Hospitalier Universitaire (CHU) de Dijon
    Full Title: CIRCULATE- CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II
    Medical condition: stage II colon cancer, after tumour resection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-005208-26 Sponsor Protocol Number: P13/12 Start Date*: 2016-02-22
    Sponsor Name:Centre Hospitalier de Versailles
    Full Title: CANDIDATE THERAPIES IN COMBINATION OR SEQUENTIALLY WITH TYROSINE KINASE INHIBITORS IN CHRONIC PHASE CHRONIC MYELOGENOUS LEUKAEMIA (CP-CML) PATIENTS IN COMPLETE CYTOGENETIC RESPONSE WITHOUT ACHIEVIN...
    Medical condition: CHRONIC PHASE CHRONIC MYELOGENOUS LEUKAEMIA (CP-CML)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10058246 Chronic myelogenous leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-002644-87 Sponsor Protocol Number: B1481021 Start Date*: 2013-11-27
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A 52 WEEK, PHASE 3 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED,PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF PF-04950615 IN SUBJECTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLE...
    Medical condition: Heterozygous Familial Hypercholesterolemia
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004861 10020604 Hypercholesterolemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) GB (Completed) NL (Completed) NO (Completed) ES (Completed) IT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2012-000344-10 Sponsor Protocol Number: Start Date*: 2012-05-24
    Sponsor Name:Medical Research Council [...]
    1. Medical Research Council
    2. Kings College London
    Full Title: Adjunctive Rifampicin to Reduce Early mortality from Staphylococcus aureus bacteraemia: a randomised controlled trial
    Medical condition: S. aureus bacteraemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10058887 Staphylococcus aureus bacteremia LLT
    14.1 10021881 - Infections and infestations 10054638 Staphylococcus aureus septicemia LLT
    14.1 10021881 - Infections and infestations 10058863 Staphylococcus aureus bacteraemia LLT
    14.1 10021881 - Infections and infestations 10041943 Staphylococcus aureus septicaemia LLT
    14.1 10021881 - Infections and infestations 10058867 Methicillin-resistant staphylococcal aureus sepsis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-003908-14 Sponsor Protocol Number: M-2020-371 Start Date*: 2021-07-07
    Sponsor Name:Miltenyi Biomedicine GmbH
    Full Title: A pivotal Phase II randomised, multi-centre, open-label study to evaluate the efficacy and safety of MB-CART2019.1 compared to standard of care therapy in participants with relapsed/refractory diff...
    Medical condition: Relapsed/refractory diffuse large B cell lymphoma (R-R DLBCL)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003903 B-cell lymphoma refractory PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003902 B-cell lymphoma recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) LT (Trial now transitioned) AT (Trial now transitioned) NL (Trial now transitioned) BE (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) HU (Trial now transitioned) CZ (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-001468-23 Sponsor Protocol Number: TG4010.14 Start Date*: 2011-12-19
    Sponsor Name:Transgene S.A.
    Full Title: A Phase IIb/III randomized, double-blind, placebo-controlled study comparing first-line therapy with or without TG4010 immunotherapy product in patients with stage IV non-small cell lung cancer (NS...
    Medical condition: Stage IV non small cell lung cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10025055 Lung cancer non-small cell stage IV LLT
    19.0 100000004864 10025048 Lung cancer non-small cell recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) HU (Completed) GB (Completed) DE (Prematurely Ended) ES (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-003595-12 Sponsor Protocol Number: ADVL1322-VEG116731 Start Date*: 2013-09-04
    Sponsor Name:GlaxoSmithKline
    Full Title: A Phase II Study of Pazopanib in Children, Adolescents and Young Adults with Refractory Solid Tumors.
    Medical condition: relapsed solid tumours in children, adolescents and young adults.
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA CZ (Completed) SK (Completed) ES (Completed) HU (Completed) FR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 27 20:09:10 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA